
Press Release|Articles|May 15, 2025
Camber Pharmaceuticals Announces Addition of Temozolomide Capsules, USP
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, USP to the portfolio.
Temozolomide Capsules, USP is an alkylating drug indicated for the treatment of adults with:
- Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment
- Anaplastic astrocytoma
- Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma
- Treatment of adults with refractory anaplastic astrocytoma
Temozolomide Capsules, USP are available in the following strengths and sizes:
- 5 mg | 5 and 14 count
- 20 mg | 5 and 14 count
- 100 mg | 5 and 14 count
- 140 mg | 5 and 14 count
- 180 mg | 5 and 14 count
- 250 mg | 5 count
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5